Sickle Cell Disease Treatment Market to Reach USD 8.75 Billion by 2029; Increasing Prevalence of Sickle Cell Disorders to Fuel Industry Growth

The global sickle cell disease treatment market size is expected to exhibit strong growth by reaching USD 8.75 billion by 2029. Fortune Business Insights™ in its report titled “Sickle Cell Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Treatment Modality [Bone Marrow Transplant, Blood Transfusion, Pharmacotherapy {Hydroxyurea, Branded Products (Endari, Adakveo, Oxbryta, Zynteglo, PYRUKYND (Mitapivat), CTX001, Inclacumab, MGTA-145, Vamifeport (VIT-2763), ALXN1820, and FT-4202)}], By End-user (Hospitals, Specialty Clinics, and Others), and Forecast, 2022-2029” observes that the market size in 2021 stood at USD 1.73 billion and touched USD 2.25 billion in 2022. The market exhibited a CAGR of 21.4% during 2022-2029. The rising prevalence of sickle cell disorders and the launch of effective drugs are expected to foster this market’s progress.

Emmaus Medical, Inc. Entered into an Agreement with Express Scripts to Offer Access to Endari 

Emmaus Medical, Inc. signed an agreement with Express Scripts in March 2019 to provide consumers full access to its Endari healthcare program in Oman. This strategy allowed the company to enhance its brand image and expand its consumer base.

Lack of Bone Marrow Donors Hampered Industry Growth During the Pandemic

This industry was negatively affected during the COVID-19 pandemic due to lack of bone marrow donors. The alarming spike in COVID-19 infections forced governments to impose stringent government lockdown regulations, thereby hampering the number of donations. Further, the closure of production facilities created a huge shortage of medical equipment for treating sickle cell disorders. However, the post-COVID-19 phase allowed companies to continue their business activities, thereby fueling market progress after the pandemic.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/industry-reports/sickle-cell-disease-treatment-market-101009

Numerous Severities Associated with the Disease to Foster Industry Growth

Sickle cell disease treatment comprises several medical procedures developed to treat sickle cell disease. The rising adoption of highly essential treatment procedures may increase due to increasing awareness regarding the disease's severity. Further, rising medical and healthcare expenditures may foster the treatment’s adoption. Moreover, increasing focus on developing effective sickle cell disease treatment solutions is expected to foster this industry’s growth. These factors are likely to drive the sickle cell disease treatment market growth.

Several Companies Devise Partnerships to Bolster their Product Offerings

The prominent companies operating in the market devise partnerships to boost their product offerings. For example, Emmaus Life Sciences, Inc. partnered with UpScript IP Holdings, LLC. (UpScript) to offer telehealth solutions to patients suffering from sickle cell disorder in November 2021. This strategy may allow the company to enhance its offerings and elevate its brand image. Further, major players engage in product launches, innovations, research and development, mergers, industrial automation, partnerships, and acquisitions to boost their market position.

Notable Industry Development

• November 2019– Addmedica appointed Master Specialty Pharma as the exclusive distributor of Siklos in the U.K.

List of Key Players Profiled in the Report

• Bristol-Myers Squibb Company (U.S.)


• Addmedica (France)


• Novartis AG (Switzerland)


• Global Blood Therapeutics, Inc. (Pfizer Inc.) (U.S.)


• Emmaus Medical, Inc. (U.S.)


• bluebird bio Inc. (U.S.)


• Agios Pharmaceuticals, Inc. (U.S.)

Further Report Findings

• The market in U.S. stood at USD 1.05 billion in 2021 and is expected to gain a huge portion of the global sickle cell disease treatment market share in the coming years. Strong government backing and increasing collaborations are expected to foster the adoption of sickle cell disease treatments.


• In Europe, increasing sickle cell diseases and favorable reimbursement policies may facilitate the spike in sickle cell disease treatment procedures. These factors may propel market progress in the region.

Table of Segmentation